Document is current

Article History

Received: 1 June 2020

Accepted: 30 September 2020

First Online: 12 October 2020

Ethics approval and consent to participate

: For the Phase 2 part of the study, all patients provided written informed consent. Non-interventional studies in Denmark do not require Ethics approval.

: All authors provided their consent for publication of this manuscript.

: SF Thomsen has been a paid speaker for AbbVie, Eli Lilly, Novartis, Sanofi, Pierre Fabre, GSK and LEO Pharma, and has served on Advisory Boards with AbbVie, Eli Lilly, Novartis, Sanofi and LEO Pharma. He has served as an investigator for AbbVie and Novartis and received research grants from AbbVie, Novartis and Sanofi. L Skov has been a paid speaker for Pfizer, AbbVie, Eli Lilly, Novartis and LEO Pharma, and has been a consultant or served on Advisory Boards with Pfizer, AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma and Sanofi. She has served as an investigator for Pfizer, AbbVie, Eli Lilly, Novartis, Amgen, Regeneron and LEO Pharma and received research and educational grant from Pfizer, AbbVie, Novartis, Sanofi, Janssen Cilag and Leo Pharma. R Dodge and MS Hedegaard are ex-employees of Novartis Healthcare, Denmark. J Kjellberg has no disclosures to make. Tanja has received speaker fees from Abbvie, Roche, Novartis, UCB, Biogen, Eli Lilly. LEK: Speakers bureau: Pfizer, AbbVie, Amgen, UCB, BMS, Biogen, Sanofi, MSD, Novartis, Eli Lilly and Company, and Janssen pharmaceuticals.